The influence of obesity on COVID-19 disease
Not Applicable
Completed
- Conditions
- COVID-19 (SARS-CoV-2 infection) (clinical diagnosis or confirmed laboratory diagnosis) and obesity (BMI >30 kg/m²)Infections and Infestations
- Registration Number
- ISRCTN11242213
- Lead Sponsor
- ovo Nordisk Pharma S.A.
- Brief Summary
2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37342262/ (added 04/01/2024)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 5307
Inclusion Criteria
1. Patients admitted to the HCSC in hospitalization regimen (primary care health care not included) between 01/03/2020-30/06/2020 with main and/or secondary diagnosis (ICD-10 codes): U07.1, U07.2, B34.2, B97.2, J12.81, J12.89, J12.90, J18.8, J18.9 or B97.29 + [J12.89, J12, J22, J40, J80, J98.8] and registered in the BDCLIN_HCSC_COVID-19 database
2. Patients with COVID-19 microbiological diagnosis (positive PCR) and registered in the BDCLIN_HCSC_COVID-19 database from 01/03/2020 to 30/06/2020
Exclusion Criteria
Does not meet inclusion criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients with obesity (BMI =30 kg/m²) obtained from medical records of COVID-19 positive patients hospitalized in HCSC in Madrid (Spain) from 01/03/2020 to 30/06/2020
- Secondary Outcome Measures
Name Time Method